Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Gross Profit (2016 - 2025)

United Therapeutics (UTHR) has disclosed Gross Profit for 17 consecutive years, with $686.8 million as the latest value for Q4 2025.

  • Quarterly Gross Profit changed N/A to $686.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $2.8 billion for FY2025, 8.98% up from the prior year.
  • Gross Profit hit $686.8 million in Q4 2025 for United Therapeutics, down from $698.6 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $711.0 million in Q2 2025 to a low of -$70.0 million in Q4 2023.
  • Historically, Gross Profit has averaged $500.5 million across 5 years, with a median of $478.8 million in 2022.
  • Biggest five-year swings in Gross Profit: plummeted 116.18% in 2023 and later surged 33.04% in 2024.
  • Year by year, Gross Profit stood at $380.6 million in 2021, then rose by 13.69% to $432.7 million in 2022, then tumbled by 116.18% to -$70.0 million in 2023, then surged by 1051.14% to $665.8 million in 2024, then rose by 3.15% to $686.8 million in 2025.
  • Business Quant data shows Gross Profit for UTHR at $686.8 million in Q4 2025, $698.6 million in Q3 2025, and $711.0 million in Q2 2025.